Genetic Tests for Breast Cancer Detect More Mutations
By LabMedica International staff writers Posted on 28 Dec 2014 |
Image: Location of the Breast cancer 1, early onset (BRCA1) gene on chromosome 17 (Photo courtesy of Armin Kübelbeck).
A new study has demonstrated the ability of a commercial Hereditary Cancer test to detect 105% more mutations in cancer causing genes than conventional Breast Cancer (BRCA) testing alone.
The company also presented two key studies in triple negative breast cancer (TNBC) that show that another test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that their molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
An analysis of 17,142 patients with breast cancer showed 1,608 (9.5%) females were positive for at least one deleterious or suspected deleterious gene mutation. The myRisk Hereditary Cancer test (Myriad Genetics, Inc.; Salt Lake City, UT, USA) found BRCA1 and BRCA2 comprised 49% of the identified mutations, and 50% percent of the mutations were in other genes, representing a 105% increase in mutation detection over BRCA testing alone.
Scientists at the at Dana-Farber Cancer Institute (Boston, MA, USA) and several other leading cancer research institutions validated the use of Myriad’s myChoice HRD test in the neoadjuvant setting with TNBC. The myChoice HRD is the first and only comprehensive companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway. The study results demonstrated that 52% of patients with a deficiency defined by myChoice HRD responded to platinum-based treatment compared to only 10% of patients with intact homologous recombination deficiency (HRD). Importantly, 28% of patients in the deficient HRD group had a pathologic complete response compared to none in the intact HRD group.
Scientists at the Institute for Cancer Research (Sutton, UK) evaluated the use of companion diagnostic assays to evaluate 310 patients with metastatic TNBC to identify which patients would respond to carboplatin or docetaxel. A key finding from this analysis is that another of Myriad’s tests, BRACAnalysis, showed that 68% of patients with a germline BRCA mutation had an objective response to treatment with carboplatin, compared to only 33% of patients who received docetaxel. Importantly, there was no difference between carboplatin and docetaxel in patients without a germline BRCA mutation.
Richard Wenstrup, MD, chief medical officer, Myriad Genetic Laboratories, said, “Our myRisk Hereditary Cancer test is making a major scientific contribution to our understanding of hereditary cancer risk and more importantly to patient care. We believe panel testing provides valuable information and guidance both for the management of the patient and the patient's family members.” The studies were presented at the 37th Annual San Antonio Breast Cancer Symposium (SABCS), held December 9–13, 2014, in San Antonio (TX, USA).
Related Links:
Myriad Genetics, Inc.
Dana-Farber Cancer Institute
Institute for Cancer Research
The company also presented two key studies in triple negative breast cancer (TNBC) that show that another test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that their molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
An analysis of 17,142 patients with breast cancer showed 1,608 (9.5%) females were positive for at least one deleterious or suspected deleterious gene mutation. The myRisk Hereditary Cancer test (Myriad Genetics, Inc.; Salt Lake City, UT, USA) found BRCA1 and BRCA2 comprised 49% of the identified mutations, and 50% percent of the mutations were in other genes, representing a 105% increase in mutation detection over BRCA testing alone.
Scientists at the at Dana-Farber Cancer Institute (Boston, MA, USA) and several other leading cancer research institutions validated the use of Myriad’s myChoice HRD test in the neoadjuvant setting with TNBC. The myChoice HRD is the first and only comprehensive companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway. The study results demonstrated that 52% of patients with a deficiency defined by myChoice HRD responded to platinum-based treatment compared to only 10% of patients with intact homologous recombination deficiency (HRD). Importantly, 28% of patients in the deficient HRD group had a pathologic complete response compared to none in the intact HRD group.
Scientists at the Institute for Cancer Research (Sutton, UK) evaluated the use of companion diagnostic assays to evaluate 310 patients with metastatic TNBC to identify which patients would respond to carboplatin or docetaxel. A key finding from this analysis is that another of Myriad’s tests, BRACAnalysis, showed that 68% of patients with a germline BRCA mutation had an objective response to treatment with carboplatin, compared to only 33% of patients who received docetaxel. Importantly, there was no difference between carboplatin and docetaxel in patients without a germline BRCA mutation.
Richard Wenstrup, MD, chief medical officer, Myriad Genetic Laboratories, said, “Our myRisk Hereditary Cancer test is making a major scientific contribution to our understanding of hereditary cancer risk and more importantly to patient care. We believe panel testing provides valuable information and guidance both for the management of the patient and the patient's family members.” The studies were presented at the 37th Annual San Antonio Breast Cancer Symposium (SABCS), held December 9–13, 2014, in San Antonio (TX, USA).
Related Links:
Myriad Genetics, Inc.
Dana-Farber Cancer Institute
Institute for Cancer Research
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities